The THINK clinical trial: Preliminary evidence of clinical activity of NKG2D Chimeric Antigen Receptor T cell therapy (CYAD-01) in acute myeloid leukemia

The THINK clinical trial: Preliminary evidence of clinical activity of NKG2D Chimeric Antigen Receptor T cell therapy (CYAD-01) in acute myeloid leukemia

The SHRINK clinical trial: A Phase 1 study assessing the safety and clinical activity of multiple doses of CYAD-01 administered concurrently with neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer

The SHRINK clinical trial: A Phase 1 study assessing the safety and clinical activity of multiple doses of CYAD-01 administered concurrently with neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer

NKG2D as a chimeric antigen receptor – DAP10 provides optimal co-stimulation for NKG2D-based CARs

NKG2D as a chimeric antigen receptor – DAP10 provides optimal co-stimulation for NKG2D-based CARs

The LINK clinical trial: A Phase 1 study assessing the safety and clinical activity of multiple hepatic transarterial administrations of CYAD-01 in patients with unresectable liver metastases from colorectal cancer

The LINK clinical trial: A Phase 1 study assessing the safety and clinical activity of multiple hepatic transarterial administrations of CYAD-01 in patients with unresectable liver metastases from colorectal cancer

Celyad to Present Updates on CYAD-01 at the American Association for Cancer Research (AACR) Annual Meeting 2018

Celyad to Present Updates on CYAD-01 at the American Association for Cancer Research (AACR) Annual Meeting 2018

Celyad Reports 2017 Financial and Operating Results and Expected Key Milestones for 2018

Celyad Reports 2017 Financial and Operating Results and Expected Key Milestones for 2018

Celyad to Host Key Opinion Leader Meeting on CAR-T Therapy for the Treatment of Blood Cancers

Celyad to Host Key Opinion Leader Meeting on CAR-T Therapy for the Treatment of Blood Cancers

Celyad Provides Clinical Update and Strategic Outlook for 2018

Celyad Provides Clinical Update and Strategic Outlook for 2018

Letter to Shareholders - December 2017

Letter to Shareholders - December 2017

Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types

Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types

Celyad to Present at the 29th Annual Piper Jaffray Healthcare Conference

Celyad to Present at the 29th Annual Piper Jaffray Healthcare Conference

Celyad Announces Third Quarter 2017 Business Update

Celyad Announces Third Quarter 2017 Business Update